NIFEDIPINE 10 MG
NIFEDIPINE : 10 MG · DIN 00755907 · AA PHARMA INC
Health Canada status: MARKETED
What is NIFEDIPINE?
NIFEDIPINE 10 MG contains NIFEDIPINE : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 00755907, held by AA PHARMA INC, supplied as CAPSULE for ORAL administration. Health Canada currently lists it as marketed, status dated 13-Jan-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NIFEDIPINE used for?
Management of angina resulting from coronary artery spasm and chronic stable angina (effort-associated angina) in patients symptomatic despite beta blockers/nitrates or who cannot tolerate them.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00755907 |
|---|---|
| Brand name | NIFEDIPINE |
| Generic / active ingredient | NIFEDIPINE : 10 MG |
| Manufacturer | AA PHARMA INC |
| Strength | 10 MG |
| Dosage form | CAPSULE |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C08CA05 NIFEDIPINE |
| AHFS class | 24:28.08 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 13-Jan-2011 |
| Original market date | 1988-12-31 00:00:00 |
How is it administered?
Starting dose: 10 mg 3 times/day. Usual range: 10-20 mg 3 times/day. Max: 120 mg/day. Capsules must be swallowed whole. Titrate at intervals of at least 3 days.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (Section 11 header present but content truncated), though typically requires protection from light and moisture.
How is it supplied?
Bottles of 100 capsules.
Contraindications
Hypersensitivity to nifedipine or dihydropyridines; pregnancy/childbearing potential; nursing; combination with rifampicin; acute myocardial infarction; cardiovascular shock; severe hypotension.
Warnings and precautions
Not for essential hypertension or acute BP reduction. Risk of excessive hypotension, increased angina/MI upon initiation, and peripheral edema. Caution in heart failure and aortic stenosis.
What can be used instead?
Other Canadian products sharing ATC code C08CA05 NIFEDIPINE. 12 of 60 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ADALAT XL | 30 MG | TABLET (EXTENDED-RELEASE) | Mint Pharmaceuticals | MARKETED | DIN 02155907 |
| AG-NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | ANGITA PHARMA INC. | MARKETED | DIN 02511460 |
| JAMP NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | JAMP PHARMA CORPORATION | MARKETED | DIN 02511711 |
| M-NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | MANTRA PHARMA INC | MARKETED | DIN 02511649 |
| MYLAN-NIFEDIPINE EXTENDED RELEASE | 30 MG | TABLET (EXTENDED-RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02349167 |
| MYLAN-NIFEDIPINE EXTENDED RELEASE | 60 MG | TABLET (EXTENDED-RELEASE) | MYLAN PHARMACEUTICALS ULC | MARKETED | DIN 02321149 |
| NIFEDIPINE | 5 MG | CAPSULE | AA PHARMA INC | MARKETED | DIN 00725110 |
| NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | PRO DOC LIMITEE | MARKETED | DIN 02421658 |
| PMS-NIFEDIPINE ER | 60 MG | TABLET (EXTENDED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02416301 |
| PMSC-NIFEDIPINE ER | 30 MG | TABLET (EXTENDED-RELEASE) | PHARMASCIENCE INC | MARKETED | DIN 02533332 |
Who else supplies NIFEDIPINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NIFEDIPINE appears in 4 registered pack listings across 3 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.